Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 홍영미 | * |
dc.contributor.author | 김관창 | * |
dc.date.accessioned | 2017-04-25T01:04:29Z | - |
dc.date.available | 2017-04-25T01:04:29Z | - |
dc.date.issued | 2017 | * |
dc.identifier.issn | 0513-5796 | * |
dc.identifier.issn | 1976-2437 | * |
dc.identifier.other | OAK-20423 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/235015 | - |
dc.description.abstract | Purpose: Pulmonary arterial hypertension (PAH) is a fatal disease which is characterized by an increase in pulmonary arterial pressure leading to increases in right ventricular afterload. Human umbilical cord blood derived-mesenchymal stem cells (hUCB-MSCs) administered via the jugular vein have been previously shown to improve PAH by reversal treatment. However, the effect of low dosage and transfusion timing of hUCB-MSCs on PAH has not yet been clearly established. Obviously, low dosage treatment can lead to a reduction in costs. This is the first study on early transfusion effect. Materials and Methods: This study was divided into two parts. The first part is an investigation of dose-dependent effect. hUCBMSCs were administered into 3 groups of rats (UA: 3x10(6) cells, UB: 1.5x10(6) cells, UC: 3x10(5) cells) via the external jugular vein at week 1 after monocrotaline (MCT) injection. The second part is a search for optimal treatment timing in 3x10(5) cells dose of hUCBMSCs administered at day 1 for UD group (low dose of hUCB-MSCs at day 1), at day 1 and week 1 for the UE group (dual transfusion of low dose of hUCB-MSCs at day 1 and week 1) and at 1 week for the UF group (reversal treatment of low dose hUCB-MSC at week 1) after MCT injection. Results: The administration of 3x10(5) hUCB-MSCs was as effective as the 3x10(6) dose in decreasing mean right ventricle (RV) pressure and pulmonary pathological changes. Early treatment with hUCB-MSCs improved mean RV pressure, pulmonary pathological changes and heart collagen 3 protein expression levels in PAH. Conclusion: Low-dose early treatment of hUCB-MSCs is as effective as a high dose treatment of hUCB-MSCs in improving PAH although dual or reversal treatment is still more effective. | * |
dc.language | English | * |
dc.publisher | YONSEI UNIV COLL MEDICINE | * |
dc.subject | Pulmonary hypertension | * |
dc.subject | mesenchymal stem cell | * |
dc.subject | prophylaxis | * |
dc.title | Optimal Dose and Timing of Umbilical Stem Cells Treatment in Pulmonary Arterial Hypertensive Rats | * |
dc.type | Article | * |
dc.relation.issue | 3 | * |
dc.relation.volume | 58 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 570 | * |
dc.relation.lastpage | 580 | * |
dc.relation.journaltitle | YONSEI MEDICAL JOURNAL | * |
dc.identifier.doi | 10.3349/ymj.2017.58.3.570 | * |
dc.identifier.wosid | WOS:000404601400014 | * |
dc.identifier.scopusid | 2-s2.0-85016187250 | * |
dc.author.google | Lee, Hyeryon | * |
dc.author.google | Kim, Kwan Chang | * |
dc.author.google | Choi, Soo Jin | * |
dc.author.google | Hong, Young Mi | * |
dc.contributor.scopusid | 홍영미(35210025100;55841904000;56063366100) | * |
dc.contributor.scopusid | 김관창(36652690000) | * |
dc.date.modifydate | 20240415130647 | * |